Amgen co-founder William K. Bowes Jr. stands watch over the Thousand Oaks campus. When Amgen bought Onyx Pharmaceuticals for $10.4 billion in 2013, it banked on Kyprolis becoming a mainstream cancer drug to treat multiple myeloma. Amgen may soon find out whether that gamble pays off. Kyprolis is currently approved for third-line treatments, and the…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
